UCn2 and UCn3 gene transfer increased LV peak DdP/dt (systolic function) and LV peak LdP/dt (diastolic function) significantly and similarly.
The corticotropin-releasing factor (CRF)
family includes CRF and urocortins 1 (UCn1), 2 (UCn2), and 3 (UCn3). Because of the potential deleterious effects of long-term exposure to CRF and UCn1 (4, 5) , we have focused on UCn2 and UCn3 in our studies. In normal humans, expression of UCn2 mRNA is found predominantly in skin and endometrium (6); UCn3 mRNA is found in the gastrointestinal tract and endometrium (7) . Circulating levels of UCn2 and UCn3 peptide in normal humans are rarely reported due to their low concentrations. Plasma UCn2 in normal males is <0.3 ng/ml (68 pmol/l) (8) , and in normal adult women, serum samples showed mean UCn3 concentrations of 0.2 ng/ml (51 pmol/l) (9) .
The actions of UCn1, UCn2, and UCn3 are governed by the tissue distribution of their receptors, corticotropin-releasing hormone receptors 1 (CRHR1) and 2 (CRHR2). UCn1 has similar affinity for CRHR1 and CRHR2, but UCn2 and UCn3 have high affinity for CRHR2 alone. CRHR1 is predominantly expressed in brain, while CRHR2 is expressed in peripheral tissues, including vascular smooth muscle, the gastrointestinal tract, skeletal muscle, and myocardium (9, 10) . UCn2 and UCn3 peptide infusions have beneficial cardiovascular effects, and
UCn2 and stresscopin (a UCn3 homolog) have been used to treat patients with HF in early-stage clinical trials (11, 12) .
UCn2 has beneficial inotropic effects, with modest effects on cardiac myocyte 3 0 ,5 0 -cyclic adenosine monophosphate (cAMP) production. In preclinical studies in murine HF, infusion of UCn2 peptide increased left ventricular (LV) contractile function (13) . Studies in large animals (14) and clinical trials (11, 12) have demonstrated the safety and beneficial effects of UCn2 peptide infusion on LV function.
UCn3 peptide infusion, less studied, is also reported to have beneficial cardiovascular effects (15) .
An unanticipated and previously unrecognized effect of sustained elevation of plasma UCn2 is increased insulin sensitivity and glucose disposal, features that recently were shown to provide longterm resolution of insulin resistance in 2 murine models (16) . It is unknown whether UCn2 or UCn3 gene transfer influences glucose disposal in normal animals.
A direct comparison of the cardiovascular effects between brief UCn2 and UCn3 peptide infusions in human males with and without HF was only recently conducted (15) . This study compared the Giamouridis et al.
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A P R I L 2 0 (18) . LV systolic and diastolic function were assessed using the first derivative of LV pressure development (þdP/dt) and decay (ÀdP/dt), respectively. The time constant of LV pressure decline (Tau) was also measured as an added
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Giamouridis et al. (1.9 Â 10 13 gc/kg, n ¼ 12). Eight to 10 weeks later, fasting (12 h) glucose was determined, and glucose tolerance testing was performed as previously described (16) . Area under the curve was calculated for individual animals using the area under the curve analysis software in GraphPad Prism (GraphPad Software version 6.07, La Jolla, California). We then used these data (mean AE SE) to test for betweengroup differences.
NECROPSY AND TISSUE COLLECTION. Anesthetized mice underwent a terminal procedure during which blood was collected in EDTA tubes (BD Biosciences, San Jose, California) for plasma extraction after centrifugation for 10 min at 4,000 rpm and 4 C.
Organs were collected and weighed, and a part of each was fast frozen in liquid nitrogen and stored at À80 C, while another part was fixed in 10%
formalin and transferred to 70% ethanol 24 h later.
CARDIAC MYOCYTE ISOLATION AND SIZE ASSESSMENT.
Isolation of cardiac myocytes was done using methods previously described (22 Western blots were performed as described previously (18, 19) . STATISTICAL ANALYSIS. Data acquisition and analysis were done without knowledge of group identity.
Group sizes were determined by power calculations.
GraphPad Prism V6.07 software was used for statistical analysis. Data represent mean AE SE; 1-way analysis of variance and Kruskal-Wallis tests were used to detect differences in the 3 groups. Sidak and Dunn multiple comparison tests were then used to test for between-group differences (UCn2 vs. UCn3).
In some instances, when comparisons were made between 2 groups, the Student t test was used (unpaired, 1-tailed). The null hypothesis was rejected when p < 0.05.
RESULTS

PLASMA PEPTIDE CONCENTRATION AFTER GENE
TRANSFER. UCn2 and UCn3 plasma levels were measured 9.0 AE 0.2 weeks after gene transfer.
UCn2 vs. UCn3 Gene Transfer
Mice that received AAV8.UCn2 (1.9 Â 10 13 gc/kg, IV)
had a 20-fold increase in plasma UCn2 levels: control
16 AE 1 ng/ml (3,627 pmol/l); p < 0.0001 ( Figure 1E ).
Mice that received AAV8.UCn3 (1.9 Â 10 13 gc/kg, IV)
had a 70-fold elevation in plasma UCn3 level: control
7 AE 0.4 ng/ml (1,785 pmol/l); p < 0.0001 ( Figure 1E ).
HEART RATE AND BLOOD PRESSURE. Heart rate and blood pressure were obtained from untethered, conscious, unsedated mice via telemetry. The anticipated increase in nocturnal activity was associated with increases in heart rate and blood pressure during the night compared with daytime when the animals were roughly 50% less active (Table 1) . However, no overall group differences were seen in heart rate or in activity levels. ECHOCARDIOGRAPHY. Eight to 10 weeks after UCn2 or UCn3 gene transfer, EF (p < 0.0001) and velocity of circumferential fiber shortening corrected for heart rate (VCFc) (p < 0.0001) were increased in both UCn2
and UCn3 groups compared with control ( Table 2 ).
UCn2 had a greater effect than UCn3 on EF (p ¼ 0.0013) and VCFc (p < 0.0001). There was an overall reduction in end-diastolic diameter (EDD) and end-systolic diameter (ESD) (p < 0.0001 for both) ( Figure 2C ). Tau was reduced 31% and 24% by UCn2 and UCn3 gene transfer, respectively (control 8.6 AE 0.3 ms, n ¼ 9; UCn2 5.9 AE 0.6 ms, n ¼ 8; UCn3 6.5 AE 0.6 ms, n ¼ 8; p ¼ 0.002) ( Figure 2D ). CO was Circ ¼ circumference; E/A ¼ ratio of passive to active mitral inflow velocity; EDD ¼ end-diastolic diameter; EF ¼ ejection fraction; ESD ¼ end-systolic diameter; MV E ¼ passive mitral inflow velocity; VCFc ¼ velocity of circumferential fiber shortening (corrected for heart rate); other abbreviations as in Table 1 . Giamouridis et al.
FIGURE 2 In Vivo Assessment of LV Function
Eight to 10 weeks after IV delivery of AAV8.UCn2 or AAV8.UCn3 (1.9 Â 10 13 gc/kg) or saline, mice underwent physiological studies to assess LV function. Figure 1 . concentration showed no group difference ( Figure 3D ).
LV SIGNALING. There were no group differences in LV cAMP levels or PKA activity ( Figures 4A and 4B ).
LV levels of phosphorylated Ca 2þ /calmodulin-dependent protein kinase II (CaMKII, isoform a) were reduced (p ¼ 0.0024) by both UCn2 (71% reduction) and UCn3 (55% reduction) gene transfer ( Figure 4C ). We also measured LV mRNA expression of key signaling proteins ( UCn3) ( Figure 5 ). UCn3 gene transfer had no effect on fasting glucose. In addition, glucose tolerance testing confirmed a group difference in glucose clearance.
The area under the glucose-time curve showed an overall group difference (p ¼ 0.015), which was solely attributable to increased glucose clearance in mice that had received UCn2 gene transfer (p ¼ 0.02 vs.
control; p < 0.02 vs. UCn3). UCn3 gene transfer, by contrast, had no effect on glucose disposal ( Figure 5 ).
NECROPSY. Mice showed no group differences in body, liver, or lung weight (Table 4) . However, UCn2
and UCn3 gene transfer was associated with a reduction in LV weight (p ¼ 0.006) ( Table 4) . This reduction persisted when LV weight was normalized to body weight (p ¼ 0.0001) and was similarly reduced in mice that had received UCn2 or UCn3 gene transfer.
HISTOLOGY AND CARDIAC MYOCYTE SIZE. Histological inspection of transmural samples of LV and liver samples from all 3 groups showed no abnormalities in inflammatory cell infiltrates or fibrosis.
Quantification of fibrosis showed no group differences ( Figure 6 ). There were differences in cardiac 
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A P R I L 2 0 showed no group differences. In B to D, summary data are from cardiac myocytes isolated from 4 mice per group; numbers in bars denote the number of cardiac myocytes per group; p values are from 1-way ANOVA. Bars denote mean and SE. Abbreviations as in Figures 1 and 2 .
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UCn2 vs. UCn3 Gene Transfer Ca 2þ transients and SERCA2a expression does not explain the differences seen on echocardiography.
Given the similarity in LV peak þdP/dt (Figure 2) , which is less load-dependent than EF, the echocardiography differences may reflect small differences in loading conditions rather than differences in LV contractility per se.
In a previously published study, we reported that LV ÀdP/dt was not altered 6 weeks after UCn2 gene transfer in normal mice (18) , but was at 4 months. In the present study, we saw increased LV peak ÀdP/dt 9.0 AE 0.2 weeks after gene transfer of either UCn2 or UCn3. Both transgenes also reduced Tau, confirming an important effect on LV diastolic function, which was similar for both transgenes. The percent increase in LV peak þdP/dt versus control (UCn2 53%; UCn3 39%), which was confirmed by increases in the ESPVR slope (UCn2 90%; UCn3 63%), and in CO (UCn2 65%; UCn3 50%) would be anticipated to have important physiological effects, especially in the setting of HF.
DIFFERENCES IN PLASMA LEVELS OF UCn2 VERSUS
UCn3. One could argue that differences in the effects of UCn2 versus UCn3 gene transfer (on RYR2 phosphorylation and EF, for example) simply reflect differences in plasma levels of transgene: plasma UCn2
(16 ng/ml [3.6 nmol/l]) was higher than plasma UCn3 However, in a previous study, we have shown the Giamouridis et al.
effects of UCn2 gene transfer on glucose disposal are dose-dependent and absent in CRHR2-deleted mice (16) . An important consideration is whether there are variations in the clearance of these peptides from plasma, but we could find no data regarding the specific peptidases involved. A structure analysis excludes the likelihood that neprilysin or neurolysin are involved. Endothelin converting enzyme-1, which can cleave CRF and UCn1 at high agonist concentrations at CRHR1 (25) , are not known to play a role in UCn2 and UCn3 degradation.
HEART RATE AND BLOOD PRESSURE. Although the anticipated reductions in blood pressure were seen, the reductions were equivalent following UCn2 and UCn3 gene transfer, and no differences in heart rate were observed ( Table 1) . These data, obtained in untethered, unsedated mice, provide persuasive evidence that unlike the case with IV infusion of UCn3 in human subjects (26) , abnormally low blood pressure is not seen with UCn2 or UCn3 gene transfer, and there is no increase in heart rate. A plausible explanation, given that UCn2 and UCn3 peptides lower systemic vascular resistance (8, 14, 15) , is that sustained high plasma levels of these peptides are associated with blunting of vasodilator and chronotropic effects.
EFFECTS ON LV SIGNALING. UCn2 and UCn3 gene transfer equivalently reduced phosphorylation of CaMKII in LV samples ( Figure 4) . Thus, while this may have contributed to the comparable increases in LV function observed after gene transfer, it cannot be the mechanism underlying differences in the effects of UCn2 versus UCn3. CaMKII expression and activation are important determinants of cardiac function, and its inhibition enhances LV function (27) . We previously showed that UCn2 gene transfer reduces LV CaMKII expression in HF in mice (19) .
Although we speculate that reduced Thr286 phosphorylation of CaMKII may have contributed to increased LV function, we did not determine the mechanism by which increased UCn2 or UCn3 evokes this change.
We found that UCn2, but not UCn3, gene transfer reduced LV RYR2 phosphorylation (Figure 4) . Abbreviations as in Figure 1 . Giamouridis et al.
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A P R I L 2 0 1 8 : 2 4 9 -6 4 presented image magnification 7Â) 9.0 AE 0.2 weeks after intravenous injection of saline, AAV8.UCn2 (1.9 Â 10 13 gc/kg) and AAV8.UCn3
(2 Â 10 13 gc/kg). (B) Evaluation of fibrosis was performed using ImageJ software. AAV8.UCn2 and AAV8.UCn3 delivery were not associated with histological abnormalities. Standard is the control for Masson's trichrome. Con ¼ control; other abbreviations as in Figures 1 and 2 .
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